Cite

    Fazio, N. et al. (2019). Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. Expert opinion on drug metabolism and toxicology. pp. 993-1004. [Online].